Dr Ken Baker
JASMINE Sim
Professor John Isaacs
| Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management? | 2021 |
|
Professor John Isaacs
| Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment (Arthritis Research & Therapy, (2021), 23, 1, (80), 10.1186/s13075-021-02451-9) | 2021 |
|
Professor John Isaacs
| EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 | 2021 |
|
Professor John Isaacs
| Immunogenicity of biologic agents in rheumatology | 2021 |
|
Dr Dennis Lendrem
Professor John Isaacs
| Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma | 2021 |
|
Dr Dag Aarsland
Professor John O'Brien
Dr Clive Ballard
Professor John Isaacs
Professor Alan Thomas
et al. | Mild cognitive impairment: the Manchester consensus | 2021 |
|
Professor John Isaacs
Dr Arthur Pratt
| Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial | 2021 |
|
Professor John Isaacs
| Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment | 2021 |
|
Professor John Isaacs
| Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials | 2020 |
|
Professor John Isaacs
| Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials (Digestive Diseases and Sciences, (2020), 10.1007/s10620-020-06560-4) | 2020 |
|
